Omalizumab

Therapeutic Omalizumab antibody from the original Xolair® commercial drug.

Reference Standard as Aliquots

Xolair®
Filters Sort results
Reset Apply
Product Batch
Therapeutic Expiry Date
Brand & Origin
Amount per Aliquot
Select Quantity
Discount
Price per Aliquot
2026.05
Xolair®
DE
6 mg
Max: 8
Min: 1
Step: 1
Unit: aliquot(s)
251,00 /aliquot

Biosimilars as Aliquots​

Filters Sort results
Reset Apply
No results found. Clear filters and try again?

Access Batch Specific Analytical Information

Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API). ​

Request an Offer​

and Download a Sample Report​

1. Choose your method(s) of interest
2. Provide your contact details
3. Send us your request and receive a downloadable sample report


Please provide your contact information


send us your inquiry and download a free sample file


Product Information

Here you will find the product information for the reference product.

Xolair® / Omalizumab Reference Product

Drug nameXolair®
INNOmalizumab
API typeMonoclonal antibody
Pharmacotherapeutic group
Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases
ATC code
R03DX05
Target of antibody
IgE
General function
Short descriptionOmalizumab is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily highdose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Omalizumab binds to IgE and prevents binding of IgE to FcεRI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade. Treatment of atopic subjects with omalizumab resulted in a marked down-regulation of FcεRI receptors on basophils. Treatment with Omalizumab inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL4, IL-5, and IL-13 by innate, adaptive and non-immune cells.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)The in vitro histamine release from basophils isolated from Omalizumab-treated subjects was reduced by approximately 90% following stimulation with an allergen compared to pre-treatment values.
In clinical studies in allergic asthma patients, serum free IgE levels were reduced in a dose-dependent manner within one hour following the first dose and maintained between doses. One year after discontinuation of Omalizumab dosing, the IgE levels had returned to pre-treatment levels with no observed rebound in IgE levels after washout of the medicinal product.
Original license holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Marketing authorisation numbers
EU/1/05/319/001
Marketing authorisation holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Name of the manufacturer of the biological active substance
Novartis Pharma S.A.S.
Centre de Biotechnologie
8, rue de l’Industrie
F-68330 Huningue
France

Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.
BioProduction Operations Singapore
8 Tuas Bay Lane
Singapore 636986
Singapore
Name and address of the manufacturer(s) responsible for batch releaseNovartis Pharma GmbH
Roonstrasse 25
D-90429 Nuremberg
Germany
Max shelf life
4 years
Storage conditions
2°C – 8°C
List of excipients
Sucrose
L-histidine
L-histidine hydrochloride monohydrate
Polysorbate 20

Support

Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!

Ready to simplify your sourcing?

Here’s how to get started:

Select Your Licensed Molecules

Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!

Get a Quote

Receive a confidential, non-binding quote for the molecule(s) you choose.

Get Qualified & We Deliver

Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.

Do you have a question you'd like to ask us?

Here’s how to get started:

Reach out to our team - we'd be happy to help you!

Thank you for your interest in our services.

We will respond to you within one working day. You can now download your sample report.